GlassScriptPhysician profile
Vijay K Sharma
NPI 1962475822
$2,795.69
in general payments reported to CMS, 2019-2025
23 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $504 · 2021: $380 · 2022: $412 · 2023: $874 · 2024: $288 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $736.28 | 2019-2025 | Breztri, Airsupra |
| Abbvie INC. | $302.17 | 2021-2023 | Qulipta, Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $280.02 | 2023-2025 | |
| Esperion Therapeutics, INC. | $237.31 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $198.04 | 2023-2024 | Rexulti |
| Abbott Laboratories | $186.81 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $179.96 | 2020-2023 | Rybelsus, Ozempic |
| Dexcom, INC. | $156.66 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Stryker Corporation | $112.16 | 2019 | |
| Lilly USA, LLC | $97.96 | 2020-2024 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $49.27 | 2023-2024 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $46.90 | 2021-2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $35.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $29.13 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $20.83 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $20.27 | 2024 | Senza |
| Seqirus USA INC | $18.68 | 2021 | |
| Organogenesis INC. | $16.83 | 2022 | |
| Renalytix Ai, INC. | $16.78 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Pfizer INC. | $16.30 | 2024 | |
| Daiichi Sankyo INC. | $13.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.83 | 2023 | Jardiance, Synjardy |
| Medicure Pharma INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.